Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Behoavy Mahafaly Ralaizanaka, Chantelli Iamblaudiot Razafindrazoto, Eloïse Bolot, Georges Bors, Stéphanie Housson-Wetzel, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy & Pierre Claude. (2022) Gastrointestinal Mucormycosis-Induced Massive Lower Gastrointestinal Bleeding, Rectal Perforation, and Pulmonary Embolism: A Long Diagnostic Pathway in a Case Report. Clinical and Experimental Gastroenterology 15, pages 145-151.
Read now
Read now
Matthew W. McCarthy & Thomas J. Walsh. (2016) Emerging diagnostic and therapeutic options for treating mucormycosis. Expert Opinion on Orphan Drugs 4:12, pages 1253-1261.
Read now
Read now
Laura L. Kovanda, Rochelle Maher & William W. Hope. (2016) Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology 9:7, pages 887-897.
Read now
Read now
Monica A Donnelley, Elizabeth S Zhu & George R Thompson$suffix/text()$suffix/text(). (2016) Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infection and Drug Resistance 9, pages 79-86.
Read now
Read now
Suganthini Krishnan Natesan & Pranatharthi H Chandrasekar. (2016) Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infection and Drug Resistance 9, pages 291-300.
Read now
Read now
Maria N Chitasombat & Dimitrios P Kontoyiannis. (2015) The ‘cephalosporin era’ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy 16:10, pages 1543-1558.
Read now
Read now
Seyedmojtaba Seyedmousavi, Paul E Verweij & Johan W Mouton. (2015) Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Review of Anti-infective Therapy 13:1, pages 9-27.
Read now
Read now
Diego R Falci & Alessandro C Pasqualotto. (2013) Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infection and Drug Resistance 6, pages 163-174.
Read now
Read now
Articles from other publishers (45)
Cecilia G. Carvalhaes, Paul R. Rhomberg, Michael D. Huband, Michael A. Pfaller & Mariana Castanheira. (2023) Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific. Journal of Fungi 9:2, pages 241.
Crossref
Crossref
Pankaj Chandley, Priyanka Subba & Soma Rohatgi. (2022) COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic. Vaccines 10:8, pages 1266.
Crossref
Crossref
Andrew M. Borman, Mark Fraser, Zoe Patterson, Michael D. Palmer & Elizabeth M. Johnson. (2021) In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles. Journal of Fungi 7:4, pages 271.
Crossref
Crossref
Somayyeh Heydari, Davood Habibi, Ali Reza Faraji, Hassan keypour & Masoumeh Mahmoudabadi. (2021) An overview on the progress and development on the palladium catalyzed direct cyanation. Inorganica Chimica Acta 514, pages 119956.
Crossref
Crossref
Frederic Lamoth & Dimitrios P. Kontoyiannis. (2019)
Therapeutic Challenges of Non-
Aspergillus
Invasive Mold Infections in Immunosuppressed Patients
. Antimicrobial Agents and Chemotherapy 63:11.
Crossref
Crossref
Jon Salmanton-García, Danila Seidel, Philipp Koehler, Sibylle C Mellinghoff, Raoul Herbrecht, Nikolai Klimko, Zdeněk Ráčil, Iker Falces-Romero, Paul Ingram, Miguel-Ángel Benítez-Peñuela, José Yesid Rodríguez, Guillaume Desoubeaux, Aleksandra Barać, Carolina García-Vidal, Martin Hoenigl, Sanjay R Mehta, Matthew P Cheng, Galina Klyasova, Werner J Heinz, Nousheen Iqbal, Robert Krause, Helmut Ostermann, Olaf Penack, Enrico Schalk, Donald C Sheppard, Birgit Willinger, Hilmar Wisplinghoff, J Janne Vehreschild, Oliver A Cornely, Maria J G T Vehreschild, Reham Abdelaziz Khedr, Alberto Arencibia-Núñez, Martha Avilés-Robles, Ingo Banke, Ariful Basher, Keertilaxmi Benachinamardi, Harmut Bertz, Arunaloke Chakrabarti, Lubos Drgona, Jesús García-Martínez, Julio García-Rodríguez, Sandra Gräber, Georg Härter, Michael Klein, Michal Kouba, Dong-Gun Lee, Yohann Le Govic, Fabian Leo, Johan Maertens, Georg Maschmeyer, Lisa Meintker, Xiao-Dong Mo, Lena-Katharina Müller, Nicolas Müller, Jeremy Stephen Nel, Jan Novák, Atul Patel, Frieder Pfäfflin, Juan-Carlos Pozo-Laderas, Pedro Puerta-Alcalde, Azucena Rodríguez-Guardado, Roland Schroers, Vandana Shekar, Susan Shenoi, Gerda Silling, Donald Vinh, Salomón Waizel-Haiat, Mandy Yap Yee Yee, Peralam Yegneswaran Prakash & Pavel Žák. (2019) Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy 74:11, pages 3315-3327.
Crossref
Crossref
William R Otto, Barbara A Pahud & Dwight E Yin. (2019) Pediatric Mucormycosis: A 10-Year Systematic Review of Reported Cases and Review of the Literature. Journal of the Pediatric Infectious Diseases Society 8:4, pages 342-350.
Crossref
Crossref
Brad Spellberg & Johan Maertens. 2019. Principles and Practice of Transplant Infectious Diseases. Principles and Practice of Transplant Infectious Diseases
577
589
.
Michael A. Pfaller, Paul R. Rhomberg, Nathan P. Wiederhold, Connie Gibas, Carmita Sanders, Hongxin Fan, James Mele, Laura L. Kovanda & Mariana Castanheira. (2018)
In Vitro
Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
. Antimicrobial Agents and Chemotherapy 62:10.
Crossref
Crossref
I. Hadrich & A. Ayadi. (2018) Epidemiology of antifungal susceptibility: Review of literature. Journal de Mycologie Médicale 28:3, pages 574-584.
Crossref
Crossref
Galen M. Kabulski & Shawn H. MacVane. (2018) Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Transplant Infectious Disease 20:3.
Crossref
Crossref
J. Denis, M.-P. Ledoux, Y. Nivoix & R. Herbrecht. (2018) Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. Journal de Mycologie Médicale 28:1, pages 8-14.
Crossref
Crossref
J. Poissy, T. Duburcq, C. Thieffry, E. Decrucq-Parmentier & D. Mathieu. (2017) « Nouvelles » molécules anti-infectieuses. Quelle place en médecine intensive/réanimation pour l’isavuconazole ?“New” drugs for infectious diseases: Can isavuconazole be used in intensive care?. Médecine Intensive Réanimation.
Crossref
Crossref
Derek Murrell, John B. Bossaer, Ronald Carico, Sam Harirforoosh & David Cluck. (2017) Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections. International Journal of Pharmacy Practice 25:1, pages 18-30.
Crossref
Crossref
Teclegiorgis Gebremariam, Nathan P. Wiederhold, Abdullah Alqarihi, Priya Uppuluri, Nkechi Azie, John E. EdwardsJrJr & Ashraf S. Ibrahim. (2017) Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. Journal of Antimicrobial Chemotherapy 72:2, pages 462-466.
Crossref
Crossref
Matt Shirley & Lesley J. Scott. (2016) Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis. Drugs 76:17, pages 1647-1657.
Crossref
Crossref
Amit Desai, Laura Kovanda, Donna Kowalski, Qiaoyang Lu, Robert Townsend & Peter L. Bonate. (2016) Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi. Antimicrobial Agents and Chemotherapy 60:9, pages 5483-5491.
Crossref
Crossref
Shawn R. Lockhart & Elizabeth L. Berkow. (2016) Hot Topics in Antifungal Susceptibility Testing: a New Drug, a Bad Bug, Sweeping Caspofungin Testing under the Rug, and Solving the Epidemiological Cutoff Value Shrug. Clinical Microbiology Newsletter 38:13, pages 103-108.
Crossref
Crossref
Nathan P. Wiederhold & Deanna A. Sutton. 2016. Biology of Microfungi. Biology of Microfungi
451
467
.
Anuradha Chowdhary, Pradeep Kumar Singh, Shallu Kathuria, Ferry Hagen & Jacques F. Meis. (2015) Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrobial Agents and Chemotherapy 59:12, pages 7882-7887.
Crossref
Crossref
Maiken Cavling Arendrup, Rasmus Hare Jensen & Joseph Meletiadis. (2015)
In Vitro
Activity of Isavuconazole and Comparators against Clinical Isolates of the
Mucorales
Order
. Antimicrobial Agents and Chemotherapy 59:12, pages 7735-7742.
Crossref
Crossref
Alessandro Busca, Anna Maria Tortorano & Livio Pagano. (2015) Reviewing the importance and evolution of fungal infections and potential antifungal resistance in haematological patients. Journal of Global Antimicrobial Resistance 3:4, pages 237-241.
Crossref
Crossref
Marisa H. Miceli & Carol A. Kauffman. (2015) Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clinical Infectious Diseases 61:10, pages 1558-1565.
Crossref
Crossref
Jeffrey M. Rybak, Kayleigh R. Marx, Andrew T. Nishimoto & P. David Rogers. (2015) Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:11, pages 1037-1051.
Crossref
Crossref
Jose F. Camargo, Danny Yakoub & Jeong Hee Cho-Vega. (2015) Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole. Mycopathologia 180:3-4, pages 187-192.
Crossref
Crossref
Marisa H. Miceli & Carol A. Kauffman. (2015) Treatment Options for Mucormycosis. Current Treatment Options in Infectious Diseases 7:3, pages 142-154.
Crossref
Crossref
Natasha N. Pettit & Peggy L. Carver. (2015) Isavuconazole. Annals of Pharmacotherapy 49:7, pages 825-842.
Crossref
Crossref
Eric Myers & Elizabeth Dodds Ashley. (2015) Antifungal Drug Therapeutic Monitoring: What are the Issues?. Current Clinical Microbiology Reports 2:2, pages 55-66.
Crossref
Crossref
Michelle R Ananda-Rajah & Dimitrios Kontoyiannis. (2015) Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiology 10:5, pages 693-708.
Crossref
Crossref
Oliver A. Cornely, Angelika Böhme, Anne Schmitt-Hoffmann & Andrew J. Ullmann. (2015) Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study. Antimicrobial Agents and Chemotherapy 59:4, pages 2078-2085.
Crossref
Crossref
J. Viljoen, N. Azie, A.-H. Schmitt-Hoffmann & M. Ghannoum. (2015) A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis. Antimicrobial Agents and Chemotherapy 59:3, pages 1671-1679.
Crossref
Crossref
Paul R. Ingram, Arul E. Suthananthan, Ruben Rajan, Todd M. Pryce, Kishore Sieunarine, Dianne J. Gardam & Christopher H. Heath. (2014) Cutaneous mucormycosis and motor vehicle accidents: Findings from an Australian case series. Medical Mycology 52:8, pages 819-825.
Crossref
Crossref
B. Rammaert & O. Lortholary. (2014) Diagnostic et traitement des mucormycoses en 2014Diagnosis and Treatment of Mucormycosis in 2014. Réanimation 23:3, pages 309-316.
Crossref
Crossref
Guanpingsheng Luo, Teclegiorgis Gebremariam, Hongkyu Lee, John E. EdwardsJr.Jr., Laura Kovanda & Ashraf S. Ibrahim. (2014) Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis. Antimicrobial Agents and Chemotherapy 58:4, pages 2450-2453.
Crossref
Crossref
J. Ervens, M. Ghannoum, B. Graf & S. Schwartz. (2013) Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection 42:2, pages 429-432.
Crossref
Crossref
Russell E Lewis & Dimitrios P Kontoyiannis. (2013) Epidemiology and treatment of mucormycosis. Future Microbiology 8:9, pages 1163-1175.
Crossref
Crossref
Michael A. Pfaller, Shawn A. Messer, Paul R. Rhomberg, Ronald N. Jones & Mariana Castanheira. (2013)
In Vitro
Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds
. Journal of Clinical Microbiology 51:8, pages 2608-2616.
Crossref
Crossref
Benoit Pilmis, Fanny Lanternier & Olivier Lortholary. (2013) Mucormycoses. médecine/sciences 29, pages 25-30.
Crossref
Crossref
B. Rammaert, F. Lanternier, S. Poirée, R. Kania & O. Lortholary. (2012) Diabetes and mucormycosis: A complex interplay. Diabetes & Metabolism 38:3, pages 193-204.
Crossref
Crossref
Brad Spellberg, Ashraf Ibrahim, Emmanuel Roilides, Russel E. Lewis, Olivier Lortholary, George Petrikkos, Dimitrios P. Kontoyiannis & Thomas J. Walsh. (2012) Combination Therapy for Mucormycosis: Why, What, and How?. Clinical Infectious Diseases 54:suppl_1, pages S73-S78.
Crossref
Crossref
Andreas H. Groll & Dominik Schrey. (2010) The Current Role of Posaconazole in Managing Zygomycosis. Current Fungal Infection Reports 5:1, pages 29-33.
Crossref
Crossref
A. Chakrabarti, M. R. Shivaprakash, I. Curfs-Breuker, A. Baghela, C. H. Klaassen & J. F. Meis. (2010)
Apophysomyces elegans
: Epidemiology, Amplified Fragment Length Polymorphism Typing, and
In Vitro
Antifungal Susceptibility Pattern
. Journal of Clinical Microbiology 48:12, pages 4580-4585.
Crossref
Crossref
Fraser F. Fleming, Lihua Yao, P. C. Ravikumar, Lee Funk & Brian C. Shook. (2010) Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry 53:22, pages 7902-7917.
Crossref
Crossref
George R. Thompson & Nathan P. Wiederhold. (2010) Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole. Mycopathologia 170:5, pages 291-313.
Crossref
Crossref
Jennifer Christoff, Jodi-Lynn Galaydick, Charulata Ramaprasad, David Pitrak & Kathleen M. Mullane. (2010) Current Diagnosis and Management of Mucormycoses. Current Fungal Infection Reports 4:1, pages 8-16.
Crossref
Crossref